Kenvue (NYSE:KVUE) Announces Earnings Results, Meets Expectations

Kenvue (NYSE:KVUE) issued its quarterly earnings data on Thursday. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26, Zacks reports. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue updated its FY 2025 guidance to 1.440-1.469 EPS.

Kenvue Stock Down 4.6 %

Kenvue stock traded down $0.96 during midday trading on Thursday, reaching $19.78. The stock had a trading volume of 25,806,069 shares, compared to its average volume of 12,576,146. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market capitalization of $37.93 billion, a P/E ratio of 35.97, a PEG ratio of 2.05 and a beta of 1.45. The company has a fifty day moving average price of $21.70 and a two-hundred day moving average price of $21.95. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 4.15%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on KVUE shares. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Bank of America lifted their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a report on Monday. Finally, JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average target price of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.